Seroatlas · Human Serome Atlas

POLR2L

DNA-directed RNA polymerases I, II, and III subunit RPABC5

Also known as: hRPB7.6, hsRPB10b, RBP10, RPAB5_HUMAN, RPABC5, RPB10beta, RPB7.6

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: P62875
Gene: POLR2L
Ensembl: ENSG00000177700
Chromosome: 11
Canonical length: 67 aa
Protein class: Metabolic proteins, Plasma proteins, Predicted intracellular proteins, RNA polymerase related proteins
Subcellular location: Nucleoplasm

OverviewNCBI Gene

This gene encodes a subunit of RNA polymerase II, the polymerase responsible for synthesizing messenger RNA in eukaryotes. The product of this gene contains four conserved cysteines characteristic of an atypical zinc-binding domain. Like its counterpart in yeast, this subunit may be shared by the other two DNA-directed RNA polymerases. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

67 residues, UniProt reviewed canonical sequence.

>P62875|POLR2L
     1  MIIPVRCFTC GKIVGNKWEA YLGLLQAEYT EGDALDALGL KRYCCRRMLL AHVDLIEKLL
    61  NYAPLEK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against POLR2L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.41
Highest tissue expression: 166 nTPM

Expression across tissuesHPA

Tissue

choroid plexus: 166 nTPM
heart muscle: 165 nTPM
kidney: 126 nTPM
pancreas: 118 nTPM
adipose tissue: 115 nTPM
liver: 110 nTPM

Single-cell type

hepatocytes: 1,884 nCPM
esophageal suprabasal cells: 1,019 nCPM
megakaryocytes: 1,008 nCPM
parietal cells: 979 nCPM
decidual stromal cells: 917 nCPM
hofbauer cells: 870 nCPM

Immune cell

plasmacytoid DC: 141 nTPM
total PBMC: 134 nTPM
NK-cell: 124 nTPM
eosinophil: 122 nTPM
classical monocyte: 120 nTPM
myeloid DC: 114 nTPM

Brain region

choroid plexus: 94 nTPM
hypothalamus: 63 nTPM
hippocampal formation: 56 nTPM
midbrain: 53 nTPM
thalamus: 52 nTPM
pons: 51 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.95
gnomAD pLI: 0
gnomAD missense Z: 0.08
DepMap mean gene effect: -2.36
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

DNA-directed RNA polymerase subunit RPABC5/Rpb10
RNA polymerases, subunit N, zinc binding site
RNA polymerase subunit RPB10
RNA polymerases N / 8 kDa subunit

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of POLR2L in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads POLR2L as an antibody target. Whether an autoantibody or antibody against POLR2L could matter depends on whether native POLR2L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

POLR2L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label POLR2L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...